About 7 million people in the United States have impaired vision, making vision loss one of the most common disabilities among American adults, the U.S. Centers for Disease Control and Prevention (CDC) reports. The CDC also warns that early detection and treatment are key in stopping the progression of vision loss—but that advice could change as new kinds of therapies show promise for restoring eyesight.

Anesthetizing the Eye Could ‘Reboot’ Vision

A research team at the Massachusetts Institute of Technology (MIT) may have found a cure for a common kind of vision loss that is effective in patients of all ages. In their study, published in the journal Cell Reports in November 2025, the MIT team tested whether anesthetizing a faulty retina could “reboot” vision, according to researchers—and it actually worked.

According to a co-author of the study, Mark Bear, PhD, their recent findings could reshape the way we think about vision loss.

The study focused on a particular kind of vision impairment called amblyopia—more commonly known as the lazy eye. Amblyopia typically starts in childhood when another underlying condition causes communication to break down between the eyes and the brain. In patients with amblyopia, the brain gradually becomes dependent on the “good” eye, causing vision in the unused eye to decline.

Current methods aren’t always successful, especially if the patients are inconsistent with topical treatments or have already reached adulthood.

The team’s new experimental treatment offers a different approach—one that doesn’t require patients to remember daily medication. In the study, the researchers anesthetized the retinas in mice’s lazy eyes with a chemical called tetrodotoxin, which some spiny species like pufferfish and porcupines naturally carry. After the treatment disabled the eyes for two days, researchers saw restored visual responses in the mice’s visual cortexes, the area of the brain that processes information from the eyes. In other words, the bad eye “could be inactivated and ‘brought back to life,’” Bear explains in a press release, meaning the researchers found what is essentially a biological reset button.

Bear says in an email that the next step for the team’s research is to recreate the experiment on other species with more advanced visual systems, as the treatment method is invasive and human eyes are complex. But they’re “cautiously optimistic that these findings may lead to a new treatment” for patients with amblyopia in the future.

A Revolutionary Retina Implant Enables Artificial Vision

An estimated five million people are unable to see the world around them because they suffer from an advanced form of age-related macular degeneration (AMD) called geographic atrophy. The condition destroys photoreceptors in the retina, which play a key role in turning light into images in your brain. Patients gradually lose their central vision, which experts previously thought was irreparable. But now a tiny device, smaller than a single grain of rice, could change that.

Experts across 17 different hospitals developed the photovoltaic retina implant microarray (PRIMA) system, which is a device that is helping blind patients regain their ability to read. In an ongoing clinical trial across five countries, the team found that the chip was effective in 84 percent of patients. After treatment, patients on average were able to read five lines of a standard vision chart, whereas before the implant, some patients were unable to distinguish the chart at all. The results of the trial were published in the New England Journal of Medicine in October 2025. The current trial will continue for the next three years, Palanker writes in an email.

“In the history of artificial vision, this represents a new era,” co-author of the study Mahi Muqit, PhD, says in a University College London (UCL) press statement. “Blind patients are actually able to have meaningful central vision restoration, which has never been done before.”

The innovative prosthesis is the culmination of 20 years of imagination, Daniel Palanker, PhD, the creator of PRIMA and co-author of the October paper, explains in a Stanford University press release. Around 2005, when he was working with lasers to treat other eye conditions, Palanker had an epiphany: researchers should take advantage of the fact that eyes are transparent and deliver information by light.

In the two decades since his realization, researchers have brought PRIMA to life. The treatment begins by surgically inserting a 2-by-2-millimeter microchip beneath the patient’s central retina. After a few weeks of recovery, the patient’s implant is remotely activated and syncs with a pair of high-tech glasses. A camera mounted on the glasses captures images and transmits them directly to the chip via infrared light, a frequency that is invisible to the naked eye. Then, the chip converts the images into electrical signals, effectively acting as artificial photoreceptors to regenerate vision. Patients wear a pocket-sized computer at the waist, which has buttons to zoom in and out.

What makes PRIMA particularly remarkable is how the chip operates completely remotely—previous retina implants required wiring and external power sources—making it much more practical. Palanker also explains that the device stands out because patients are actually regaining their sight, not just seeing flashes and shadows like other retinal prostheses induce.

According to Science Corporation, the neuroscience technology company involved in developing PRIMA, future applications include treating retinitis pigmentosa and Stargardt disease, which are both eye conditions that cause substantial vision loss. Meaning, researchers seem to be closer than ever to curing blindness for good.

Regenerated Retinal Cells Could Reverse Blindness

For decades, scientists have been looking for some way to regrow retinal neuron cells in mammals. Roughly 300 million people worldwide have some form of retinal degeneration, which can seriously reduce vision and even cause blindness.

In 2025, a team at The Korea Advanced Institute of Science and Technology found promising results in experiments with mice, particularly because mice are also mammals and share similar traits. In a Nature Communications study published in late March 2025, the scientists detail a novel method that they claim can restore vision.

The Korea Institute’s team gets around a mammalian inability to reprogram damaged Müller glial cells, whose role is to maintain the functionality of retinal cells. Some animals, such as zebrafish, can replace damaged cells with functional retinal neurons.

Müller glial cells maintain the functionality of retinal cells by suppressing a protein called PROX1, which inhibits the development of different retinal cell types in mammals. Researchers noticed in their experiments that PROX1 tended to accumulate in mouse Müller glial cells—which act as support cells for retinal neurons—after an injury.

By blocking PROX1—and so preventing the suppression of new retinal cells—the team sustained retinal regeneration in mice with retinitis pigmentosa, a disease that occurs when photoreceptors in the retina deteriorate. The effects of the regeneration lasted for six months, allowing the scientists to boldly declare that this was the “first successful induction of long-term neural regeneration in mammalian retinas.”

Since the eye is an extremely complex organ, scientists around the world have been investigating different molecular mechanisms that could be responsible for our inability to regrow retinal neurons. One of these was a 2019 study that looked into the “Hippo pathway,” which keeps retinal regeneration dormant.

And a 2022 study published in Oxford Open Neuroscience found that when amphibians’ retinal cells are damaged, these animals have “ciliary marginal zone cells” that go to work proliferating new retinal cells. The study also discussed experiments on mice that demonstrated how certain genetic modifications can improve retinal regeneration. “In many animal tissues that contain stem cells … degenerated cells are replenished by new cells, allowing these tissues to maintain their functions despite continuous cell loss,” the authors wrote.

Recently, other scientists have taken a more hardware-centric approach, developing methods that use gold nanoparticles stimulated by lasers to circumvent damaged photoreceptors. This method can also stimulate cells located further up the visual chain and could be useful for the condition retinitis pigmentosa and macular degeneration.

Whether through hardware or cellular intervention, science is quickly helping humanity gain some regenerative ground on other members of the animal kingdom, who do it naturally.

Human Eye Cells Could ‘Rewind’ to a Younger State

Yuri Deigin, cofounder of Seattle-based YouthBio Therapeutics, wants to reverse-age human organs, and his process will likely start with the eyes.

The idea rests on a deceptively simple premise: aging is not simply damage, but a program. “My view is that the epigenome [theset of chemical switches that control how genes are turned on and off] is the closest thing biology has to a writable operating system that helps determine cellular age,” Deigin says. As cells grow older, this epigenome drifts, becomes noisier, and loses some of its precision. The goal of what scientists call partial cellular reprogramming is to reset that system, pushing cells back toward a younger, more functional state without erasing their identity.

Deigin is focusing on building a set of genes known as the Yamanaka factors, which are powerful regulators that can reset a cell’s biological clock by changing its gene expression patterns. But instead of fully activating the Yamanaka factors, researchers are trying to pulse them just enough to restore function without wiping their identity. In practice, that means delivering the genes that encode these factors into specific, aging organs such as eyes, and activating them in controlled bursts, potentially through periodic activation.

At Boston biotech company Life Biosciences, researchers are testing an approach that aims to coax damaged optic nerve cells back into a more youthful state. In animal studies, this has improved aspects of vision after injury and pushed cells toward younger patterns of function, says Sharon Rosenzweig-Lipson, PhD, the company’s chief scientific officer. The work has now moved into an early human trial, where the company is testing its lead therapy, ER-100, in people with optic nerve damage. For now, the goal is modest: to see if some of that lost function can be restored safely. “Near term, these therapies have the potential to restore function in specific tissues that are impacted by aging,” she says.